(Q38161580)

30 August 2017

Optimal use of phosphate binders in chronic kidney disease (English)

1 reference

30 August 2017

Makrouhi Sonikian

1

1 reference

30 August 2017

Evangelos Papachristou

series ordinal

2

1 reference

30 August 2017

Dimitrios S Goumenos

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

Expert Opinion on Pharmacotherapy

30 August 2017

1 reference

30 August 2017

14

1 reference

30 August 2017

18

1 reference

30 August 2017

2521-2532

1 reference

Medication-induced hypophosphatemia: a review

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Endocrine functions of bone in mineral metabolism regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Klotho converts canonical FGF receptor into a specific receptor for FGF23

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Klotho deficiency causes vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Determinants of progressive vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

The role of phosphorus in the development and progression of vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effect of the time of administration of calcium acetate on phosphorus binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

A comparison of clinically useful phosphorus binders for patients with chronic kidney failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Intestinal absorption of aluminium in renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Arterial calcifications and bone histomorphometry in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Improving phosphate-binder therapy as a way forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

The phosphate binder equivalent dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Cardiovascular effects of sevelamer in stage 3 CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Ten-year experience with sevelamer and calcium salts as phosphate binders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.852183

10.1517/14656566.2013.852183

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference